The aim of the present trial is to evaluate whether the conversion of immunosuppression from
tacrolimus to cyclosporine A induces changes in (i) hepatitis C-virus load, (ii) parameters
of hepatic function and (iii) parameters of glucose tolerance in hepatitis C-positive renal
transplant recipients.